Table 1.
Baseline characteristics and subregional cartilage thickness among patients treated with 100 μg sprifermin and matched placebo‐treated patientsa
| 100 μg sprifermin (n = 57) | Matched placebo (n = 18) | |||
|---|---|---|---|---|
| Characteristic | ||||
| Age, mean ± SD years | 61.2 ± 9.1 | 60.9 ± 6.9 | ||
| Female, no. (%) | 39 (68.4) | 12 (66.7) | ||
| BMI, mean ± SD kg/m2 | 30.5 ± 5.0 | 31.5 ± 5.3 | ||
| K/L grade 3, no. (%) | 29 (50.9) | 11 (61.1) | ||
| Time since OA onset, mean ± SD years | 7.1 ± 5.4 | 7.4 ± 3.7 | ||
| Cartilage subregion thickness, mean ± SD μm | ||||
| cMT | 2,189.5 ± 556.1 | 2,236.1 ± 560.5 | ||
| eMT | 1,194.4 ± 378.9 | 1,168.9 ± 427.1 | ||
| iMT | 1,858.6 ± 329.6 | 1,871.1 ± 269.3 | ||
| aMT | 1,487.2 ± 251.8 | 1,453.9 ± 345.9 | ||
| pMT | 1,408.6 ± 223.4 | 1,478.3 ± 263.9 | ||
| ccMF | 1,920.4 ± 658.4 | 1,800.0 ± 738.1 | ||
| ecMF | 1,281.8 ± 393.0 | 1,265.0 ± 367.3 | ||
| icMF | 1,772.6 ± 383.5 | 1,740.0 ± 419.1 | ||
| cLT | 2,775.3 ± 869.6 | 2,593.9 ± 813.4 | ||
| eLT | 1,431.1 ± 393.9 | 1,370.6 ± 542.3 | ||
| iLT | 1,790.0 ± 438.7 | 1,758.3 ± 280.6 | ||
| aLT | 1,585.6 ± 305.0 | 1,628.3 ± 319.3 | ||
| pLT | 1,653.3 ± 427.9 | 1,484.4 ± 316.3 | ||
| ccLF | 2,157.0 ± 416.5 | 2,205.6 ± 546.1 | ||
| ecLF | 1,563.5 ± 348.1 | 1,550.0 ± 456.8 | ||
| icLF | 1,681.4 ± 308.9 | 1,759.4 ± 400.3 | ||
a
Thickness of cartilage from the medial tibia (MT), central part of the medial weight‐bearing femur (cMF), lateral tibia (LT), and central part of the lateral weight‐bearing femur (cLF) was determined in the central (c), external (e), internal (i), anterior (a), and posterior (p) subregions. BMI = body mass index; K/L = Kellgren/Lawrence; OA = osteoarthritis.